Healthcare
Kezar Life Sciences, Inc.(KZR)
Live Price
Offline$7.29
+0.00% today
Window Change
+78.24%
Window
Jun 25, 2025 โ May 11, 2026
- Market Cap
- $50.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -566.1%
- Dividend Yield
- 0.0%
Coverage: 221 bars ยท Jun 25, 2025 โ May 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kezar Life Sciences, Inc. (KZR) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $7.29 and up 78.2% across the available one-year price window (Jun 25, 2025 โ May 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -566.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -566.1%, free cash flow +30.2% with operating margin 0.0% and ROIC -72.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KZR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -566.1%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 31, 2026 | -52.0% | -0.3% | -0.5% | -1.6% |
2025 Nov 12, 2025 | +15.5% | -0.2% | +0.6% | +2.3% |
2025 Aug 13, 2025 | +13.0% | +1.5% | -0.5% | +1.5% |
Benchmark Edge
KZR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KZR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KZR Max Drawdown
-25.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KZR and SPY.
Company Overview
Kezar Life Sciences, Inc.
NASDAQ Global Select
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
- Leadership
- Christopher J. Kirk
- IPO Date
- Jun 21, 2018
- Employees
- 55
- Street Address
- 4000 Shoreline Court
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 822 5600
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.3
- Price/Sales
- โ
- Price/Book
- 0.8
Growth
- Revenue
- 0.0%
- EPS
- -566.1%
- Free Cash Flow
- +30.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -64.4%
- ROIC
- -72.2%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 11.52
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.